Skip to main content
. 2022 Nov 14;33:100939. doi: 10.1016/j.ymgmr.2022.100939

Table 1.

Relative difference in erythrocyte protoporphyrin and serum iron levels for study completers.

3.

*Stopped study drug early due to primary safety endpoint being met (35% increase in ePPIX over baseline).

Green indicates an improvement in levels from baseline to end of study.

#Month 12 serum iron testing not done due to sample error.

$Discontinued iron due to increased EPP symptoms.